GlassScriptPhysician profile
Chukwuma Egwim
NPI 1265607725
$144,719.10
in general payments reported to CMS, 2019-2025
39 companies · $34K in 2025
The $34K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $6,976 · 2021: $16K · 2022: $13K · 2023: $16K · 2024: $27K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $8,864 · Consulting Fee: $8,488 · Travel and Lodging: $7,024 · Honoraria: $6,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,808.50 |
| Food and Beverage | $8,864.14 |
| Consulting Fee | $8,487.50 |
| Travel and Lodging | $7,024.31 |
| Honoraria | $6,450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $101,505.80 | 2019-2025 | Vemlidy, Livdelzi |
| Madrigal Pharmaceuticals | $33,023.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,268.28 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,838.43 | 2019-2025 | Mavyret, Avycaz, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $715.08 | 2019-2025 | Livtencity, Gattex, Vpriv |
| Intercept Pharmaceuticals, INC. | $632.35 | 2019-2024 | Ocaliva |
| Intra-Sana Laboratories | $600.33 | 2021-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ipsen Biopharmaceuticals, INC | $480.11 | 2023-2025 | Iqirvo, Bylvay |
| Shionogi INC | $405.48 | 2019-2020 | |
| Fujifilm Healthcare Americas Corporation | $292.41 | 2021-2022 | |
| Eisai INC. | $231.79 | 2020-2021 | |
| Dova Pharmaceuticals | $217.55 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $185.02 | 2021-2025 | Terlivaz |
| Novo Nordisk INC | $176.16 | 2019-2025 | Wegovy, Saxenda |
| Albireo Pharma, INC. | $130.71 | 2023 | Bylvay |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $119.51 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $95.61 | 2019-2020 | |
| Evoke Pharma, INC. | $95.25 | 2020-2024 | Gimoti |
| Orphalan INC | $91.03 | 2024-2025 | Cuvrior |
| Qol Medical, LLC | $62.53 | 2022-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $56.97 | 2022 | |
| Mirum Pharmaceuticals, INC. | $52.53 | 2025 | Livmarli |
| Sobi, INC | $45.14 | 2021 | |
| Phathom Pharmaceuticals, INC. | $42.29 | 2024 | Voquezna |
| Biocompatibles, INC. | $39.74 | 2019 | |
| Vivus LLC | $39.47 | 2021-2025 | Pancreaze |
| Alfasigma USA, INC. | $33.86 | 2020 | |
| Merck Sharp & Dohme LLC | $33.29 | 2019 | |
| Endo Pharmaceuticals INC. | $30.13 | 2019 | |
| Romark Laboratories, Lc | $26.32 | 2019 | |
| Sirtex Medical INC | $21.94 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.88 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.42 | 2022 | |
| Vifor Pharma, INC. | $18.35 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.69 | 2019 | |
| Teleflex LLC | $15.90 | 2021 | |
| Allergan, INC. | $13.88 | 2020 | |
| Capsovision, INC. | $13.80 | 2025 | Capsocam Plus |
| Celgene Corporation | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuma Egwim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.